Skip to content

Roche Reports Robust 2024 Germany Growth, Plans 2025 Innovations

Roche's focus on innovation and employee development fuels growth. New diagnostic products and regulatory extensions planned for 2025.

In this image i can see a bottle with a name of discovery on it.
In this image i can see a bottle with a name of discovery on it.

Roche Reports Robust 2024 Germany Growth, Plans 2025 Innovations

Pharmaceutical giant Roche has reported robust growth in Germany, with a turnover of 8.5 billion euros in 2024. The company, which employs 18,256 people in the country, invested 653 million euros in expanding and modernizing its German sites. Roche's commitment to innovation has driven 70% of its pharmaceuticals division turnover from products introduced since 2020.

Roche's diagnostics division contributed significantly to this growth, with a turnover of 812 million euros, marking a 0.8% increase. Meanwhile, the pharmaceuticals division generated 2.1 billion euros, despite a slight decrease of 0.7%. The company's success can be attributed to its focus on innovation and employee development. In 2025, Roche plans to introduce innovative diagnostic products like the VENTANA HER2 (4B5) companion diagnostic test and advanced mass spectrometry-based diagnostic assays such as the Ionify 25-Hydroxy Vitamin D total test. Roche also seeks regulatory extensions for new pharmaceutical forms and strengths of drugs like Mosunetuzumab (Lunsumio).

Roche's board member, Dr. Daniel Steiners, emphasizes the importance of a welcoming culture for innovations in Germany. The company views itself as a key player in the industrial health economy and is committed to training and further education for its employees.

Roche's stable growth in Germany, with a turnover increase of 2.6% compared to the previous year, underscores the company's commitment to innovation and employee development. As it continues to invest in its German sites and introduce new diagnostic products and treatments, Roche solidifies its position as a major contributor to the country's health economy.

Read also:

Latest